We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says Teva's Agilect Is 'Approvable,' But Concerns Remain
FDA Says Teva's Agilect Is 'Approvable,' But Concerns Remain
August 9, 2005
Teva Pharmaceutical’s expected U.S. launch of its new Parkinson’s disease drug Agilect has been delayed for a second time after the FDA informed the company that it still has concerns about the firm’s new drug application (NDA) for the product.